Gilead Sciences (GILD) : Oakbrook Investments scooped up 175,605 additional shares in Gilead Sciences during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Apr 14, 2016. The investment management firm now holds a total of 337,070 shares of Gilead Sciences which is valued at $33,130,610.Gilead Sciences makes up approximately 2.11% of Oakbrook Investments’s portfolio.
Gilead Sciences opened for trading at $98.17 and hit $99.73 on the upside on Monday, eventually ending the session at $99.2, with a gain of 0.93% or 0.91 points. The heightened volatility saw the trading volume jump to 80,67,829 shares. Company has a market cap of $135,591 M.
Other Hedge Funds, Including , Acadian Asset Management reduced its stake in GILD by selling 985 shares or 6.28% in the most recent quarter. The Hedge Fund company now holds 14,693 shares of GILD which is valued at $1,444,175. Gilead Sciences makes up approx 0.01% of Acadian Asset Management’s portfolio.1st Global Advisors boosted its stake in GILD in the latest quarter, The investment management firm added 1,746 additional shares and now holds a total of 5,688 shares of Gilead Sciences which is valued at $559,074. Gilead Sciences makes up approx 0.08% of 1st Global Advisors’s portfolio.Banced Corp boosted its stake in GILD in the latest quarter, The investment management firm added 2,583 additional shares and now holds a total of 15,179 shares of Gilead Sciences which is valued at $1,491,944. Gilead Sciences makes up approx 2.59% of Banced Corp’s portfolio.Hays Advisory reduced its stake in GILD by selling 11,250 shares or 11.83% in the most recent quarter. The Hedge Fund company now holds 83,879 shares of GILD which is valued at $8,244,467. Gilead Sciences makes up approx 1.16% of Hays Advisory’s portfolio.Rowland Co Investment Counseladv boosted its stake in GILD in the latest quarter, The investment management firm added 81 additional shares and now holds a total of 1,133 shares of Gilead Sciences which is valued at $111,363. Gilead Sciences makes up approx 0.05% of Rowland Co Investment Counseladv’s portfolio.
On the company’s financial health, Gilead Sciences reported $3.32 EPS for the quarter, beating the analyst consensus estimate by $ 0.34 according to the earnings call on Feb 2, 2016. Analyst had a consensus of $2.98. The company had revenue of $8506.00 million for the quarter, compared to analysts expectations of $8163.83 million. The company’s revenue was up 16.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.43 EPS.
Many Wall Street Analysts have commented on Gilead Sciences. Shares were Reiterated by Leerink Partners on Mar 16, 2016 to “Outperform” and Lowered the Price Target to $ 127 from a previous price target of $130 .Citigroup Initiated Gilead Sciences on Feb 25, 2016 to “Buy”, Price Target of the shares are set at $110.Shares were Reiterated by Maxim Group on Feb 12, 2016 to “Buy” and Lowered the Price Target to $ 115 from a previous price target of $137 .
Gilead Sciences Inc. (Gilead) is a research-based biopharmaceutical company that discovers develops and commercializes innovative medicines. The Companys primary areas of focus include human immunodeficiency virus (HIV) liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection oncology and inflammation and serious cardiovascular and respiratory conditions. The Companys HIV products include Stribild Complera/Eviplera Atripla Truvada Viread Emtriva Tybost and Vitekta. Its Liver Diseases products include Harvoni Sovaldi Viread and Hepsera. Zydelig is the Companys oncology product. Its Cardiovascular products include Letairis Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.